脑心通胶囊联合左旋氨氯地平片治疗原发性高血压的临床研究

中国基层医药 Pub Date : 2020-03-15 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.06.017

Zhiyong Li

{"title":"脑心通胶囊联合左旋氨氯地平片治疗原发性高血压的临床研究","authors":"Zhiyong Li","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.06.017","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the clinical effect of Naoxintong capsule combined with levamlodipine tablets in the treatment of essential hypertension. \n \n \nMethods \nFrom February 2018 to February 2019, 182 cases of essential hypertension were selected in Jiangshan Hospital of Traditional Chinese Medicine and divided into treatment group (91 cases) and control group (91 cases) according to the random digital table.The treatment group was treated with Naoxintong capsule combined with levamlodipine tablets, while the control group was treated with levamlodipine tablets.Both two groups were treated for 12 weeks.The therapeutic effects, blood pressure, urinary microalbumin (MAU), vascular endothelial function and inflammatory mediators before and after treatment were compared between the two groups. \n \n \nResults \nThe total effective rate of the treatment group[91.21%(83/91)]was higher than that of the control group[79.12%(72/91)](χ2=5.262, P<0.05). After treatment, SBP[(132.36±8.27)mmHg], DBP[(84.35±5.32)mmHg]and MAU[(26.47±5.47)mg/L] in the treatment group were lower than those in the control group[(139.62±6.58)mmHg, (89.74±4.12)mmHg and (33.82±3.76)mg/L](t=6.553, 7.641, 10.563, all P<0.05). The NO[(52.17±5.36)μmol/L]and FMD[(7.98±0.42)%] in the treatment group were higher than those in the control group[(41.09±7.28)μmol/L and (6.79±0.37)%], while ADMA[(0.23±0.06)μmol/L]in the treatment group was lower than that in the control group[(0.34±0.07)μmol/L], the differences were statistically significant(t=11.692, 20.281, 11.382, all P<0.05). The serum levels of IL-1[(128.32±13.25)ng/L] and IL-4[(24.35±5.71)ng/L] in the treatment group were lower than those in the control group[(173.79±23.19)ng/L and (32.19±6.57)ng/L], while the serum IL-10 level[(23.54±3.25)ng/L] in the treatment group was higher than that in the control group[(18.09±4.86)ng/L], the differences were statistically significant(t=16.240, 8.592, 8.892, all P<0.05). \n \n \nConclusion \nNaoxintong capsule combined with levamlodipine tablets is effective in the treatment of essential hypertension, which can reduce MAU, improve vascular endothelial dysfunction and alleviate inflammation. \n \n \nKey words: \nHypertension; Therapeutic effect; Urinary microalbumin; Vascular endothelial function; Inflammatory mediator; Naoxintong capsule; Levamlodipine tablet","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":"27 1","pages":"719-723"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical study of Naoxintong capsule combined with levamlodipine tablets in the treatment of essential hypertension\",\"authors\":\"Zhiyong Li\",\"doi\":\"10.3760/CMA.J.ISSN.1008-6706.2020.06.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo investigate the clinical effect of Naoxintong capsule combined with levamlodipine tablets in the treatment of essential hypertension. \\n \\n \\nMethods \\nFrom February 2018 to February 2019, 182 cases of essential hypertension were selected in Jiangshan Hospital of Traditional Chinese Medicine and divided into treatment group (91 cases) and control group (91 cases) according to the random digital table.The treatment group was treated with Naoxintong capsule combined with levamlodipine tablets, while the control group was treated with levamlodipine tablets.Both two groups were treated for 12 weeks.The therapeutic effects, blood pressure, urinary microalbumin (MAU), vascular endothelial function and inflammatory mediators before and after treatment were compared between the two groups. \\n \\n \\nResults \\nThe total effective rate of the treatment group[91.21%(83/91)]was higher than that of the control group[79.12%(72/91)](χ2=5.262, P<0.05). After treatment, SBP[(132.36±8.27)mmHg], DBP[(84.35±5.32)mmHg]and MAU[(26.47±5.47)mg/L] in the treatment group were lower than those in the control group[(139.62±6.58)mmHg, (89.74±4.12)mmHg and (33.82±3.76)mg/L](t=6.553, 7.641, 10.563, all P<0.05). The NO[(52.17±5.36)μmol/L]and FMD[(7.98±0.42)%] in the treatment group were higher than those in the control group[(41.09±7.28)μmol/L and (6.79±0.37)%], while ADMA[(0.23±0.06)μmol/L]in the treatment group was lower than that in the control group[(0.34±0.07)μmol/L], the differences were statistically significant(t=11.692, 20.281, 11.382, all P<0.05). The serum levels of IL-1[(128.32±13.25)ng/L] and IL-4[(24.35±5.71)ng/L] in the treatment group were lower than those in the control group[(173.79±23.19)ng/L and (32.19±6.57)ng/L], while the serum IL-10 level[(23.54±3.25)ng/L] in the treatment group was higher than that in the control group[(18.09±4.86)ng/L], the differences were statistically significant(t=16.240, 8.592, 8.892, all P<0.05). \\n \\n \\nConclusion \\nNaoxintong capsule combined with levamlodipine tablets is effective in the treatment of essential hypertension, which can reduce MAU, improve vascular endothelial dysfunction and alleviate inflammation. \\n \\n \\nKey words: \\nHypertension; Therapeutic effect; Urinary microalbumin; Vascular endothelial function; Inflammatory mediator; Naoxintong capsule; Levamlodipine tablet\",\"PeriodicalId\":10226,\"journal\":{\"name\":\"中国基层医药\",\"volume\":\"27 1\",\"pages\":\"719-723\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国基层医药\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.06.017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.06.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的观察脑心通胶囊联合左旋氨氯地平片治疗原发性高血压的临床疗效。方法选取江山市中医院2018年2月至2019年2月收治的182例原发性高血压患者，根据随机数字表分为治疗组91例和对照组91例。治疗组采用脑心通胶囊联合左旋氨氯地平片治疗，对照组采用左旋氨氯平片治疗。两组均接受为期12周的治疗。比较两组治疗前后的疗效、血压、尿微量白蛋白（MAU）、血管内皮功能和炎症介质。结果治疗组总有效率[91.21%（83/91）]明显高于对照组[79.12%（72/91））（χ2=5.262，治疗组DBP[（84.35±5.32）mmHg]和MAU[（26.47±5.47）mg/L]均低于对照组[（139.62±6.58）mmHg、（89.74±4.12）mmHg和（33.82±3.76）mg/L]（t=6.553、7.641、10.563，均P<0.05）。）%]，治疗组ADMA[（0.23±0.06）μmol/L]低于对照组[（0.34±0.07）μmol/L]，差异有统计学意义（t=11.692、20.281、11.382，均P<0.05），治疗组血清IL-10水平[（23.54±3.25）ng/L]高于对照组[（18.09±4.86）ng/L].差异有统计学意义（t=16.240，8.592，8.892，均P<0.05），改善血管内皮功能障碍，减轻炎症。关键词：高血压；治疗效果；尿微量白蛋白；血管内皮功能；炎症介质；脑心通胶囊；左旋氨氯地平片

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical study of Naoxintong capsule combined with levamlodipine tablets in the treatment of essential hypertension

Objective To investigate the clinical effect of Naoxintong capsule combined with levamlodipine tablets in the treatment of essential hypertension. Methods From February 2018 to February 2019, 182 cases of essential hypertension were selected in Jiangshan Hospital of Traditional Chinese Medicine and divided into treatment group (91 cases) and control group (91 cases) according to the random digital table.The treatment group was treated with Naoxintong capsule combined with levamlodipine tablets, while the control group was treated with levamlodipine tablets.Both two groups were treated for 12 weeks.The therapeutic effects, blood pressure, urinary microalbumin (MAU), vascular endothelial function and inflammatory mediators before and after treatment were compared between the two groups. Results The total effective rate of the treatment group[91.21%(83/91)]was higher than that of the control group[79.12%(72/91)](χ2=5.262, P<0.05). After treatment, SBP[(132.36±8.27)mmHg], DBP[(84.35±5.32)mmHg]and MAU[(26.47±5.47)mg/L] in the treatment group were lower than those in the control group[(139.62±6.58)mmHg, (89.74±4.12)mmHg and (33.82±3.76)mg/L](t=6.553, 7.641, 10.563, all P<0.05). The NO[(52.17±5.36)μmol/L]and FMD[(7.98±0.42)%] in the treatment group were higher than those in the control group[(41.09±7.28)μmol/L and (6.79±0.37)%], while ADMA[(0.23±0.06)μmol/L]in the treatment group was lower than that in the control group[(0.34±0.07)μmol/L], the differences were statistically significant(t=11.692, 20.281, 11.382, all P<0.05). The serum levels of IL-1[(128.32±13.25)ng/L] and IL-4[(24.35±5.71)ng/L] in the treatment group were lower than those in the control group[(173.79±23.19)ng/L and (32.19±6.57)ng/L], while the serum IL-10 level[(23.54±3.25)ng/L] in the treatment group was higher than that in the control group[(18.09±4.86)ng/L], the differences were statistically significant(t=16.240, 8.592, 8.892, all P<0.05). Conclusion Naoxintong capsule combined with levamlodipine tablets is effective in the treatment of essential hypertension, which can reduce MAU, improve vascular endothelial dysfunction and alleviate inflammation. Key words: Hypertension; Therapeutic effect; Urinary microalbumin; Vascular endothelial function; Inflammatory mediator; Naoxintong capsule; Levamlodipine tablet

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.